Journal article
Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy
Cancers, Vol.13(7), p.1489
03/24/2021
DOI: 10.3390/cancers13071489
PMCID: PMC8037963
PMID: 33804910
Abstract
Brain metastases commonly develop in melanoma and are associated with poor overall survival of about five to nine months. Fortunately, new therapies, including immune checkpoint inhibitors and BRAF/MEK inhibitors, have been developed. The aim of this study was to identify outcomes of different treatment strategies in patients with melanoma brain metastases in the era of checkpoint inhibitors. Patients with brain metastases secondary to melanoma were identified at a single institution. Univariate and multivariable analyses were performed to identify baseline and treatment factors, which correlated with progression-free and overall survival. A total of 209 patients with melanoma brain metastases were identified. The median overall survival of the cohort was 5.3 months. On multivariable analysis, the presence of non-cranial metastatic disease, poor performance status (ECOG 2-4), whole-brain radiation therapy, and older age at diagnosis of brain metastasis were associated with poorer overall survival. Craniotomy (HR 0.66, 95% CI 0.45-0.97) and treatment with a CTLA-4 checkpoint inhibitor (HR 0.55, 95% CI 0.32-0.94) were the only interventions associated with improved overall survival. Further studies with novel agents are needed to extend lifespan in patients with brain metastases in melanoma.
Details
- Title: Subtitle
- Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy
- Creators
- John M Rieth - Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USAUmang Swami - Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT 84112, USASarah L Mott - Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USAMario Zanaty - Department of Neurosurgery, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USAMichael D Henry - Department of Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USAAaron D Bossler - Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USAJeremy D Greenlee - Department of Neurosurgery, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USAYousef Zakharia - Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USAMarion Vanneste - Department of Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USABrooke Jennings - Department of Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USAMohammed M Milhem - Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
- Resource Type
- Journal article
- Publication Details
- Cancers, Vol.13(7), p.1489
- DOI
- 10.3390/cancers13071489
- PMID
- 33804910
- PMCID
- PMC8037963
- NLM abbreviation
- Cancers (Basel)
- ISSN
- 2072-6694
- eISSN
- 2072-6694
- Publisher
- Switzerland
- Grant note
- P30 CA086862 / NCI NIH HHS 5881CC12 / Iowa Department of Public Health
- Language
- English
- Date published
- 03/24/2021
- Academic Unit
- Molecular Physiology and Biophysics; Hematology, Oncology, and Blood & Marrow Transplantation; Pathology; Iowa Neuroscience Institute; Radiation Oncology; Radiation Research Laboratory; Urology; Neurosurgery; Otolaryngology; Internal Medicine
- Record Identifier
- 9984068355402771
Metrics
30 Record Views